Drug Study – Ranitidine

by: ishi21, RN

Zantac, Zantac EFFERdose, Zantac GELdose, Zantac-75

Action:

Potent anti-ulcer drug that competitively and reversibly inhibits histamine action at H₂-receptor sites on parietal cells, thus blocking gastric acid secretion. Indirectly reduces pepsin secretion but appears to have minimal effect on fasting and postprandial serum gastrin concentrations or secretion of gastric intrinsic factor or mucus

Classifications:

GASTROINTESTINAL AGENT; ANTISECRETORY (H2-RECEPTOR ANTAGONIST)

Indication:

Short-term treatment of active duodenal ulcer; maintenance therapy for duodenal ulcer patient after healing of acute ulcer; treatment of gastroesophageal reflux disease; short-term treatment of active, benign gastric ulcer; treatment of pathologic GI hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, and postoperative hypersecretion); heartburn.

DOWNLOAD

Related posts:

1. RANITIDINE HYDROCHLORIDE (ra-nye’te-deen) Zantac, Zantac EFFERdose, Zantac GELdose, Zantac-75 Classifications: gastrointestinal agent;...
2. Drug Study – Losartan Potassium Cozaar Action: Angiotensin II receptor (type AT1) antagonist acts as...
3. Drug Study – Diazepam Action: Psychotherapeutic agent related to chlordiazepoxide; reportedly superior in antianxiety...
4. Drug Study – ATROPINE SULFATE Acts by selectively blocking all muscarinic responses to acetylcholine (ACh),...
5. Drug Study – AMINOPHYLLINE Aminophylline is a salt of theophylline with effects similar to...

Advertisements: